<DOC>
	<DOCNO>NCT02594800</DOCNO>
	<brief_summary>Atherosclerotic intracranial arterial stenosis ( AICAS ) correspond luminal narrow major intracranial artery . The prevalence intracranial atherosclerotic stenosis account 33 % 67 % stroke transient ischemic attack ( TIA ) case China country Asia . AICAS also highly associate risk stroke recurrence . Possible mechanisms cerebral infarction secondary AICAS likely link hemodynamic compromise distal site stenosis . Computed tomography perfusion ( CTP ) use evaluate vasoreactivity cerebrovascular reserve patient AICAS predict future stroke . The parameter CTP include ①cerebral blood flow ( CBF ) , ② cerebral blood volume ( CBV ) ③mean transit time ( MTT ) . Relative regional cerebral blood flow ( rCBF ) evaluate percentage radioisotope count region interest ( ROI ) affect side correspond ROI unaffected contralateral side . Statins decrease incidence transient ischemic attack ischemic stroke improve stroke outcome . Few study focus relationship statin therapy cerebral perfusion . Whether intensive rosuvastatin therapy compare standard rosuvastatin therapy improve hemodynamic situation cerebral perfusion status AICAS illustrate . Based study , investigator hypothesize intensive rosuvastatin may also improve symptom AICAS enhance stability atherosclerotic plaque , also pleiotropic effect . So change hemodynamic status around plaque increase cerebral flow downstream territory . So study investigator try analysis statin 's impact hemodynamic change well downstream perfusion determine CTP .</brief_summary>
	<brief_title>Intensive Rosuvastatin Therapy Cerebral Hemodynamics Patients With Atherosclerotic Intracranial Arterial Stenosis</brief_title>
	<detailed_description>This prospective , randomize , single-blind , single center clinical trial evaluate effect intensive rosuvastatin therapy compare standard rosuvastatin therapy improve cerebral perfusion Chinese patient atherosclerotic intracranial arterial stenosis 50-99 % . The study enroll 44 patient randomly divide 2 group : standard dose rosuvastatin therapy ( SRT 10mg/day ) intensive dose rosuvastatin therapy ( IRT 20mg/day ) 1:1 ratio . Both group prescribe statin base routine medication stroke 52 week . CTP perform baseline 52 week treatment . Lipid level biochemical examination obtain baseline 13 , 26 , 39 , 52 week . AEs ( Adverse Events ) /SAEs ( Serious Adverse Events ) collect record CRF ( Case Report Form ) signing inform consent throughout study include last visit . Study Endpoints : Primary endpoint : Compared standard dose rosuvastatin therapy 10mg/day , change relative cerebral blood flow ( CBF ) CTP intensive dose rosuvastatin therapy 20mg/day treatment 52 weeks.Secondary endpoint : ( 1 ) Compared standard dose rosuvastatin therapy 10mg/day , change relative cerebral blood volume ( CBV ) CTP rosuvastatin 20mg/d treatment 52 week ( 2 ) Compared standard dose rosuvastatin therapy 10mg/day , change relative mean transit time ( MTT ) CTP rosuvastatin 20mg/d treatment 52 week ( 3 ) Compared standard dose rosuvastatin therapy 10mg/day , change lipid parameter ( LDL-C , HDL-C , TG ( Triglyceride ) , TC ( Total Cholesterol ) , Apo A Apo B ) rosuvastatin 20mg/d 52 week ( 4 ) Safety .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Provision inform consent 2 . Male female adult age 1880years old 3 . Recent ( within 3 month ) ischemic stroke TIA ; 4 . Intracranial large artery ( intracranial internal artery , middle cerebral artery M1 , vertebral artery basilar artery ) stenosis 5099 % . 5 . Statin naïve : define receive statin therapy within 3 month 1 . Cardioembolic stroke ; 2 . Rosuvastatin use contraindicate ; 3 . Allergic contrast agent ; 4 . Chronic devastate illness , multiple organ failure ; 5 . Dementia mental disorder unable return repeat brain CTP . 6 . Administration lipidlowering drug ( statin , clofibrate , probucol analog , nicotinic acid , prohibit drug ) enrollment . 7 . Active liver disease aminopherase ≧3 ULN ( Upper Limit Normal ) 8 . Renal function damage . GFR（Glomerular Filtration Rate） ﹤30ml/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Atherosclerotic Intracranial Arterial Stenosis</keyword>
	<keyword>Intensive Rosuvastatin Therapy</keyword>
	<keyword>Computed Tomography Perfusion ( CTP )</keyword>
</DOC>